EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in CRISPR/Cas9 Genome Editing for the Treatment of Muscular Dystrophies

Sina Fatehi iD, Ryan M Marks, Matthew J Rok, Lucie Perillat, Evgueni A Ivakine, Ronald D Cohn

Human Gene Therapy · 2023

DOI: 10.1089/hum.2023.059 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Human Gene Therapy, 2023. Verfasst von Sina Fatehi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Program in Genetics and Genome Biology, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children Research Institute, Toronto, On…. Hauptthemen laut MEDLINE: Gene Editing, Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 129 Literaturangaben. Gefördert von: CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Muscular dystrophies (MDs) comprise a diverse group of inherited disorders characterized by progressive muscle loss and weakness. Given the genetic etiology underlying MDs, researchers have explored the potential of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) genome editing as a therapeutic intervention, resulting in significant advances. Here, we review recent progress on the use of CRISPR/Cas9 genome editing as a potential therapy for MDs. Significant strides have been made in this realm, made possible through innovative techniques such as precision genetic editing by modified forms of CRISPR/Cas9. These approaches have shown varying degrees of success in animal models of MD, including Duchenne MD, congenital muscular dystrophy type 1A, and myotonic dystrophy type 1. Even so, there are several challenges facing the development of CRISPR/Cas9-based MD therapies, including the targeting of satellite cells, improved editing efficiency in skeletal and cardiac muscle tissue, delivery vehicle enhancements, and the host immunogenic response. Although more work is needed to advance CRISPR/Cas9 genome editing past the preclinical stages, its therapeutic potential for MD is extremely promising and justifies concentrated efforts to move into clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene EditingMuscular Dystrophy, DuchenneAnimalsCRISPR-Cas SystemsGenetic TherapyDystrophin

Stichwörter der Autor:innen

CRISPR/Cas9Duchenne muscular dystrophyadeno-associated virusesgenome editingmuscular dystrophy

Substanzen

Dystrophin

Autor:innen und Institutionen

  • Program in Genetics and Genome Biology, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada; Departments of.
  • Molecular Genetics and.
  • Physiology, University of Toronto, Toronto, Ontario, Canada.
  • Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada; and.
  • Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Sina Fatehi

Förderung

  • CIHR

Zitieren

APA

Fatehi, S., Marks, R. M., Rok, M. J., Perillat, L., Ivakine, E. A., & Cohn, R. D. (2023). Advances in CRISPR/Cas9 Genome Editing for the Treatment of Muscular Dystrophies. Human Gene Therapy. https://doi.org/10.1089/hum.2023.059

Vancouver

Fatehi S, Marks RM, Rok MJ, Perillat L, Ivakine EA, Cohn RD. Advances in CRISPR/Cas9 Genome Editing for the Treatment of Muscular Dystrophies. Human Gene Therapy. 2023. doi:10.1089/hum.2023.059

BibTeX
@article{Fatehi2023,
  author = {Fatehi, Sina and Marks, Ryan M and Rok, Matthew J and Perillat, Lucie and Ivakine, Evgueni A and Cohn, Ronald D},
  title = {Advances in CRISPR/Cas9 Genome Editing for the Treatment of Muscular Dystrophies},
  journal = {Human Gene Therapy},
  year = {2023},
  doi = {10.1089/hum.2023.059}
}
Kostenlos starten →